BACKGROUND: The relevance of the Simpson grading system as a predictor of meningioma progression or recurrence in modern neurosurgical practice has recently been called into question. The aim of our study was to compare the risk of progression/recurrence of tumours that had been treated with different Simpson grade resections in a contemporary population of benign (WHO grade I) meningioma patients. METHOD: One hundred eighty-three patients with histologically confirmed WHO grade I meningioma were retrospectively analysed. All patients underwent first-time craniotomy as their initial therapy between 2004 and 2012. Univariate analysis was performed using log-rank testing and Kaplan-Meier analysis for progression/recurrence-free survival. Multivariate analysis was performed using Cox proportional hazards regression modelling. RESULTS: The three-year progression/recurrence-free survival rates for patients receiving Simpson grade 1, 2 or 4 resections were 95 %, 87 % and 67 %, respectively. Simpson grade 4 resections progressed/recurred at a significantly greater rate than Simpson grade 1 resections (hazard ratio [HR] = 3.26, P = 0.04), whereas Simpson grade 2 resections did not progress/recur at a significantly greater rate than Simpson grade 1 resections (HR = 1.78, P = 0.29). Subtotal resections progressed/recurred at a significantly greater rate than gross-total resections (HR = 2.47, P = 0.03). CONCLUSIONS: Tumours that undergo subtotal resection are at a significantly greater risk of progression/recurrence than tumours that undergo gross-total resection. Gross-total resection should therefore be the aim of surgery. However, given modern access to follow-up imaging and stereotactic radiosurgery, these results should not be used to justify overly 'heroic' tumour resection.
BACKGROUND: The relevance of the Simpson grading system as a predictor of meningioma progression or recurrence in modern neurosurgical practice has recently been called into question. The aim of our study was to compare the risk of progression/recurrence of tumours that had been treated with different Simpson grade resections in a contemporary population of benign (WHO grade I) meningiomapatients. METHOD: One hundred eighty-three patients with histologically confirmed WHO grade I meningioma were retrospectively analysed. All patients underwent first-time craniotomy as their initial therapy between 2004 and 2012. Univariate analysis was performed using log-rank testing and Kaplan-Meier analysis for progression/recurrence-free survival. Multivariate analysis was performed using Cox proportional hazards regression modelling. RESULTS: The three-year progression/recurrence-free survival rates for patients receiving Simpson grade 1, 2 or 4 resections were 95 %, 87 % and 67 %, respectively. Simpson grade 4 resections progressed/recurred at a significantly greater rate than Simpson grade 1 resections (hazard ratio [HR] = 3.26, P = 0.04), whereas Simpson grade 2 resections did not progress/recur at a significantly greater rate than Simpson grade 1 resections (HR = 1.78, P = 0.29). Subtotal resections progressed/recurred at a significantly greater rate than gross-total resections (HR = 2.47, P = 0.03). CONCLUSIONS:Tumours that undergo subtotal resection are at a significantly greater risk of progression/recurrence than tumours that undergo gross-total resection. Gross-total resection should therefore be the aim of surgery. However, given modern access to follow-up imaging and stereotactic radiosurgery, these results should not be used to justify overly 'heroic' tumour resection.
Authors: Adriana Olar; Khalida M Wani; Charmaine D Wilson; Gelareh Zadeh; Franco DeMonte; David T W Jones; Stefan M Pfister; Erik P Sulman; Kenneth D Aldape Journal: Acta Neuropathol Date: 2017-01-27 Impact factor: 17.088
Authors: Kira Marie Voß; Dorothee Cäcilia Spille; Cristina Sauerland; Eric Suero Molina; Caroline Brokinkel; Werner Paulus; Walter Stummer; Markus Holling; Astrid Jeibmann; Benjamin Brokinkel Journal: J Neurooncol Date: 2017-05-19 Impact factor: 4.130
Authors: Farshad Nassiri; Justin Z Wang; Karolyn Au; Jill Barnholtz-Sloan; Michael D Jenkinson; Kate Drummond; Yueren Zhou; James M Snyder; Priscilla Brastianos; Thomas Santarius; Suganth Suppiah; Laila Poisson; Francesco Gaillard; Mark Rosenthal; Timothy Kaufmann; Derek S Tsang; Kenneth Aldape; Gelareh Zadeh Journal: Neuro Oncol Date: 2022-05-04 Impact factor: 13.029
Authors: Adriana Olar; Lindsey D Goodman; Khalida M Wani; Nicholas S Boehling; Devi S Sharma; Reema R Mody; Joy Gumin; Elizabeth B Claus; Frederick F Lang; Timothy F Cloughesy; Albert Lai; Kenneth D Aldape; Franco DeMonte; Erik P Sulman Journal: Oncotarget Date: 2018-02-15
Authors: Sara Alatriste-Martínez; Sergio Moreno-Jiménez; Guillermo A Gutiérrez-Aceves; José de Jesús Suárez-Campos; Olivia Amanda García-Garduño; Alejandro Rosas-Cabral; Miguel Ángel Celis-López Journal: World Neurosurg X Date: 2019-03-07